3 results
Approved WMOCompleted
The primary objective is to assess the clinical efficacy of siltuximab (a chimeric (murine-human) IgG1* mAb that specifically binds human IL-6 with high affinity and prevents its interaction with the IL-6 receptor, glycoprotein (GP) 80),…
Approved WMORecruiting
Improves the alpha blocker Silodosin the bladder emptying in patients with MS? Improves the alpha blocker Silodosin the quality of life of patients with MS?
Approved WMORecruiting
Primary objective: To investigate the clinical effectiveness of the novel anal insert (Navina* Fecal Incontinence Insert) in ambulatory patients with faecal incontinence in comparison to care as usual (e.g. incontinence pads)Secondary objectives:1.…